Scholarlink

Background <p>Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse effect of long-term bisphosphonate therapy characterized by impaired bone remodeling, inflammation, and fibrosis. Gallic acid (GA), a natural phenolic compound with potent antioxidant and anti-inflammatory properties, has been proposed as a protective agent against drug-induced tissue injury. This study investigated the prophylactic and therapeutic effects of GA on zoledronic acid (ZOA)–induced MRONJ in rats.</p> Methods <p>Thirty-two adult female Wistar albino rats were randomly divided into four groups (<i>n</i> = 8): Control, MRONJ (ZOA + tooth extraction), MRONJ + Pre-GA (prophylactic GA), and MRONJ + Post-GA (therapeutic GA). MRONJ was induced by intraperitoneal ZOA (0.06&#xa0;mg/kg/week, 5 weeks) followed by mandibular molar extraction. GA (100&#xa0;mg/kg, i.p.) was administered either before or after ZOA exposure for 7 days. Mandibular tissues were analyzed histopathologically, immunohistochemically (Fibroblast growth factor [FGF], transforming growth factor beta 1 [TGF-1β], tumor necrosis factor alpha [TNF-α]), and molecularly (TNF-α, TGF-1β, endothelial nitric oxide synthase [eNOS], cytochrome c [Cyt-C], caspase-3 [Cas-3], protein kinase RNA-like ER kinase [PERK], C/EBP homologous protein [CHOP]).</p> Results <p>MRONJ rats exhibited severe osteonecrosis, increased inflammation and fibrosis, disrupted collagen organization, elevated osteoclast activity, and suppressed osteoblast function. Immunohistochemistry revealed significant downregulation of FGF and TGF-1β with a concomitant rise in TNF-α. Gene expression analyses showed upregulation of TNF-α, TGF-1β, CHOP, PERK, Cyt-C, and Cas-3, along with downregulation of eNOS. GA administration markedly ameliorated these alterations, restoring bone architecture, normalizing growth factor expression, suppressing pro-inflammatory and apoptotic signaling, and reducing ER stress. The prophylactic regimen showed the most pronounced protective efficacy.</p> Conclusions <p>GA confers both preventive and therapeutic benefits against MRONJ by mitigating oxidative stress, inflammation, fibrosis, ER stress and mitochondrial apoptosis. These findings suggest that GA may represent a promising adjuvant strategy for managing or preventing MRONJ in patients receiving long-term antiresorptive therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Protective and therapeutic effects of gallic acid on medication-related osteonecrosis of the jaw in rats: modulation of inflammation, fibrosis and endoplasmic reticulum/mitochondrial stress pathways

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月24日

查看全文
  • Tayfun Yazıcı,
  • Mustafa Isleyen,
  • Aybike Imeci,
  • Halil Asci,
  • Muhammet Yusuf Tepebasi,
  • Abdurrahman Gülal,
  • Oznur Kolay,
  • Serife Tasan,
  • Sefa Erdem Karapınar,
  • Ozlem Ozmen

摘要

Background

Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse effect of long-term bisphosphonate therapy characterized by impaired bone remodeling, inflammation, and fibrosis. Gallic acid (GA), a natural phenolic compound with potent antioxidant and anti-inflammatory properties, has been proposed as a protective agent against drug-induced tissue injury. This study investigated the prophylactic and therapeutic effects of GA on zoledronic acid (ZOA)–induced MRONJ in rats.

Methods

Thirty-two adult female Wistar albino rats were randomly divided into four groups (n = 8): Control, MRONJ (ZOA + tooth extraction), MRONJ + Pre-GA (prophylactic GA), and MRONJ + Post-GA (therapeutic GA). MRONJ was induced by intraperitoneal ZOA (0.06 mg/kg/week, 5 weeks) followed by mandibular molar extraction. GA (100 mg/kg, i.p.) was administered either before or after ZOA exposure for 7 days. Mandibular tissues were analyzed histopathologically, immunohistochemically (Fibroblast growth factor [FGF], transforming growth factor beta 1 [TGF-1β], tumor necrosis factor alpha [TNF-α]), and molecularly (TNF-α, TGF-1β, endothelial nitric oxide synthase [eNOS], cytochrome c [Cyt-C], caspase-3 [Cas-3], protein kinase RNA-like ER kinase [PERK], C/EBP homologous protein [CHOP]).

Results

MRONJ rats exhibited severe osteonecrosis, increased inflammation and fibrosis, disrupted collagen organization, elevated osteoclast activity, and suppressed osteoblast function. Immunohistochemistry revealed significant downregulation of FGF and TGF-1β with a concomitant rise in TNF-α. Gene expression analyses showed upregulation of TNF-α, TGF-1β, CHOP, PERK, Cyt-C, and Cas-3, along with downregulation of eNOS. GA administration markedly ameliorated these alterations, restoring bone architecture, normalizing growth factor expression, suppressing pro-inflammatory and apoptotic signaling, and reducing ER stress. The prophylactic regimen showed the most pronounced protective efficacy.

Conclusions

GA confers both preventive and therapeutic benefits against MRONJ by mitigating oxidative stress, inflammation, fibrosis, ER stress and mitochondrial apoptosis. These findings suggest that GA may represent a promising adjuvant strategy for managing or preventing MRONJ in patients receiving long-term antiresorptive therapy.